NDUFS6
ENSG00000145494
Target class
Enzyme
Chromosome
5
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-13kA
- Target name
- NDUFS6
- Gene name
- NADH:ubiquinone oxidoreductase subunit S6
- Gene symbol
- NDUFS6
- Protein name
- NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial (Complex I-13kD-A) (CI-13kD-A) (NADH-ubiquinone oxidoreductase 13 kDa-A subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 98.63
- Tissue specificity (Gini)
- 0.144
- Tissue specificity (tau)
- 0.487
- KEGG gene identifiers
- hsa:4726
- Protein interaction confidence
- 0.920817
- Protein interaction partners
- 115
- R-HSA-611105
- R-HSA-6799198
- End position
- 1816051
- Start position
- 1801363
- Chromosome
- 5
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.486918
- Expression inequality (Gini)
- 0.144361
Expression in transcripts per million
- Heart - Left Ventricle
- 98.63
- Testis
- 81.44
- Muscle - Skeletal
- 79.3
- Heart - Atrial Appendage
- 78.99
- Cells - EBV-transformed lymphocytes
- 70.06
Expression in transcripts per million
- Heart - Left Ventricle98.63
- Testis81.44
- Muscle - Skeletal79.3
- Heart - Atrial Appendage78.99
- Cells - EBV-transformed lymphocytes70.06
- Kidney - Medulla69.57
- Colon - Sigmoid67.39
- Cells - Cultured fibroblasts66.82
- Esophagus - Mucosa62.06
- Esophagus - Muscularis61.26
- Esophagus - Gastroesophageal Junction59.81
- Thyroid58.53
- Artery - Aorta58.42
- Artery - Coronary57.89
- Colon - Transverse57.82
- Nerve - Tibial57.07
- Artery - Tibial56.1
- Prostate55.36
- Uterus55.28
- Fallopian Tube53.25
- Vagina52.34
- Pituitary51.82
- Adipose - Subcutaneous50.21
- Cervix - Endocervix50.13
- Breast - Mammary Tissue49.76
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0045271
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor